Tuba et al. summarized the current available data indicating that treatment with SGLT2 inhibitors transiently activates systemic RAAS, but not intrarenal RAAS, in patients with type 2 diabetes [33]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.